William Rust devoted his career to developing stem cells as therapies and research tools at ES Cell International, Lonza and the ATCC. Will launched Seraxis based on his concept for a more potent cell therapy for diabetes. For this work he was granted multiple families of patents in the US and worldwide for the technologies behind the Seraxis stem cell, the Seraxis pancreas organoid, and the technology to improve allo-compatibility. By providing successful strategic direction to the company, he was able to grow Seraxis from start-up through several rounds of financing to position Seraxis as an industry leader in islet replacement therapy for type 1 diabetes. Will earned his Ph.D. from UNLV and completed a research fellowship in the transplant department of Novartis.